-Advertisement-
-Advertisement-
FDA Alerts
FDA New Drug Approval Roundup (March 2022)
Pluctivo for PSMA-positive mCRPC The US Food and Drug Administration has approved 177Lu-PSMA-617 (Pluctivo; Novartis) for the treatment of patients with metastatic prostate-specific membrane antigen–positive metastatic castration-resistant prostate cancer (PSMA-positive mCRPC) following other therapies. Approval is based on results from the phase 3 VISION trial that demonstrated patients with treated PSMA-positive...
Read More-Advertisement-
-Advertisement-
-Advertisement=-
By rd360stg
September 29, 2021
By rd360stg
By rd360stg
-Advertisement-
-Advertisement-
-Advertisement=-
By rd360stg
By rd360stg
By rd360stg
-Advertisement-
-Advertisement-
-Advertisement-

Stay Connected! Join Our Newsletter
Contact
Grandin Library Building
Six Leigh Street
Clinton, New Jersey 08809
+908-505-8899
info@ihmholdings.com
QUICK LINKS
© 2022 IHM. RD 360 is a trademark of International Healthcare Media, LLC. All rights Reserved